share_log

Dianthus Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(5.1%),TCG Crossover Fund II, L.P.(5.1%), etc.

SEC ·  Nov 23, 2024 05:45
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more